Why Traditional Psychedelics Miss 90% of Neurology Patients - And The Solution

Inside the ALS Breakthrough: 20-Year Journey to FDA Approval with Dr. Joseph Palumbo

Why Clinical Trial Speed Kills Success - And What Top Sponsors Do Instead ft. Steve Brannan

Dr. Anantha Shekhar on the Convergence of Psychiatry, Neurology, and the Next Era of Brain Medicine

Ram Mukunda, CEO of IGC Pharma, on Innovation and Hope in Alzheimer’s Care

Brandon Bentzley, CSO and Co-founder of Magnus Medical, on Precision Psychiatry and Rewiring Depression

Sarah MacCallum & Melissa Gaines- Clinical Operations Leaders at Annovis Bio

Daniel O'Connell, CEO of Acumen Pharmaceuticals, on Oligomers, Innovation, and Hope in Alzheimer’s

Michael Gold, Chief R&D Officer at Compass Pathways

Matthew Leoni, CMO of Merida Biosciences, on Navigating the Challenges and Opportunities in Neuroscience Drug Development

Gerard Sanacora, Professor at Yale, on glutamate, GABA, and the next era of depression treatment

Backing Breakthroughs in Psychedelics

Joel Raskin, CMO of Arrivo Bio talks about unlocking the future of psychiatry

Dr. Jerry Rosenbaum & Dr. Sharmin Ghaznavi: Mass General Center on the Neuroscience of Psychedelics

Spyros Papapetropoulos, CEO of Neuphoria

Steve Gourlay, CEO of Actinogen

Boehringer Ingelheim: Christine Sakdalan and Mike Jablonski talk precision psychiatry

John Krystal: Advancing Ketamine Research & Psychiatry at Yale

Next-Gen Treatments for Anxiety and Depression Disorders

Precision Psychiatry and Emerging Technologies